**CardiAMP Heart Failure II Trial Overview** This study is for people with a type of heart failure called ischemic heart failure. Here, heart muscles are weakened due to reduced blood flow. Researchers want to test a special treatment called CardiAMP cell therapy. This therapy uses **autologous bone marrow mononuclear cells (ABM MNC)**. These are special cells taken from a person's own bone marrow that might help the heart work better. In this study, participants are divided into two groups. One group gets the CardiAMP cell therapy, while the other group undergoes a control procedure called diagnostic catheterization. This procedure involves inserting a thin tube into the heart to take pictures and measurements, but no cells are given. **Key Points:** - **Study Length:** Participants will be involved for several months, with regular follow-ups. - **Procedures:** Some participants will receive the cell therapy; others will have a diagnostic procedure. - **Risks and Benefits:** Potential benefits include improved heart function, but there may be risks like any medical procedure. Participants must have specific heart health conditions to join. This study aims to find out if this new therapy is safe and effective for improving heart health.